Jazz Pharmaceuticals is a global biopharmaceutical company that develops and commercializes life-changing medicines for patients with rare diseases, particularly in sleep disorders, epilepsies, and oncology. The company markets a diversified portfolio including Xywav (a low-sodium oxybate formulation for narcolepsy and idiopathic hypersomnia), Epidiolex (cannabidiol for rare seizure disorders), and several oncology products including treatments for biliary tract cancer, diffuse midline glioma, small-cell lung cancer, and leukemia. Jazz generates revenue primarily through direct commercial operations in developed markets and distributor networks globally, with products sold to healthcare systems, specialty pharmacies, and hospitals, while maintaining an active research and development pipeline in oncology and rare disorders supported by manufacturing facilities and contract manufacturing partners.